![]() 静脈内抗凝固薬-世界市場シェアとランキング、全体売上高と需要予測 2025-2031Intravenous Anticoagulants- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 静脈内抗凝固薬の世界市場は、2024年には100万米ドル規模になると推定され、2031年には100万米ドルに再調整され、予測期間2025-2031年のCAGRは%になると予測されている。 抗凝固剤は、血栓の形成を防ぎ、既存... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリー静脈内抗凝固薬の世界市場は、2024年には100万米ドル規模になると推定され、2031年には100万米ドルに再調整され、予測期間2025-2031年のCAGRは%になると予測されている。抗凝固剤は、血栓の形成を防ぎ、既存の血栓が大きくなるのを阻止する医薬品である。 静脈内抗凝固薬の北米市場は、2024年に100万ドルと評価され、2025年から2031年の予測期間中に年平均成長率%で、2031年までに100万ドルに達する見込みです。 静脈内抗凝固薬のアジア太平洋市場は、2024年に100万ドルと評価され、2025年から2031年の予測期間中に%のCAGRで、2031年までに100万ドルに達するだろう。 静脈内抗凝固薬のヨーロッパ市場は、2024年に100万ドルと評価され、2025年から2031年の予測期間中に%のCAGRで、2031年までに100万ドルに達するだろう。 静脈内抗凝固薬の世界の主要企業には、アスペングループ、ファイザー、サノフィ、マイラン、バイエルAG、ベーリンガーインゲルハイム、第一三共、大塚製薬、ロシュ、ザ・メディシンズ・カンパニーなどがあります。2024年には、世界の大手5社の売上高シェアは約 %となる。 本レポートは、静脈内抗凝固薬の世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総販売量、販売収益、価格、主要企業の市場シェア、ランキングに焦点を当て、包括的なプレゼンテーションを提供することを目的としています。 静脈内抗凝固薬の市場規模、推計、予測は、2024年を基準年として、2020年から2031年までの期間の履歴データおよび予測データとともに、販売数量(K単位)および販売収益(百万ドル)で提供されます。定量的および定性的な分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、静脈内抗凝固薬に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 アスペングループ ファイザー サノフィ マイラン バイエル ベーリンガーインゲルハイム 第一三共 大塚製薬 ロシュ ザ・メディシンズ・カンパニー アレクシオン レオ・ファーマ タイプ別セグメント 低分子ヘパリン(LMWH) 直接トロンビン阻害薬(DTI) その他 用途別セグメント 病院 クリニック その他 地域別 北米 アメリカ カナダ アジア太平洋 中国 日本 韓国 東南アジア インド オーストラリア その他のアジア太平洋地域 ヨーロッパ ドイツ フランス 英国 イタリア オランダ 北欧諸国 その他のヨーロッパ ラテンアメリカ メキシコ ブラジル その他のラテンアメリカ 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 その他のMEA 各章の概要 第1章: レポートの対象範囲、世界の総市場規模(金額、数量、価格)を紹介します。また本章では、市場ダイナミクス、市場の最新動向、市場の促進要因と制限要因、業界メーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章 静脈内抗凝固薬メーカーの競争環境、価格、売上高、市場シェア、最新の開発計画、合併・買収情報などを詳細に分析します。 第3章:タイプ別に様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性を網羅し、読者が異なる市場セグメントでブルーオーシャン市場を見つけるのを助ける。 第4章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのに役立ちます。 第5章:静脈内抗凝固薬の地域別売上高、収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。 第6章 静脈内抗凝固薬の国別売上高、収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章:主要企業のプロファイルを提供し、製品の売上高、収益、価格、売上総利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。 第8章:産業の上流と下流を含む産業チェーンの分析。 第9章:結論 目次1 Market Overview1.1 Intravenous Anticoagulants Product Introduction 1.2 Global Intravenous Anticoagulants Market Size Forecast 1.2.1 Global Intravenous Anticoagulants Sales Value (2020-2031) 1.2.2 Global Intravenous Anticoagulants Sales Volume (2020-2031) 1.2.3 Global Intravenous Anticoagulants Sales Price (2020-2031) 1.3 Intravenous Anticoagulants Market Trends & Drivers 1.3.1 Intravenous Anticoagulants Industry Trends 1.3.2 Intravenous Anticoagulants Market Drivers & Opportunity 1.3.3 Intravenous Anticoagulants Market Challenges 1.3.4 Intravenous Anticoagulants Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Intravenous Anticoagulants Players Revenue Ranking (2024) 2.2 Global Intravenous Anticoagulants Revenue by Company (2020-2025) 2.3 Global Intravenous Anticoagulants Players Sales Volume Ranking (2024) 2.4 Global Intravenous Anticoagulants Sales Volume by Company Players (2020-2025) 2.5 Global Intravenous Anticoagulants Average Price by Company (2020-2025) 2.6 Key Manufacturers Intravenous Anticoagulants Manufacturing Base and Headquarters 2.7 Key Manufacturers Intravenous Anticoagulants Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Intravenous Anticoagulants 2.9 Intravenous Anticoagulants Market Competitive Analysis 2.9.1 Intravenous Anticoagulants Market Concentration Rate (2020-2025) 2.9.2 Global 5 and 10 Largest Manufacturers by Intravenous Anticoagulants Revenue in 2024 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Intravenous Anticoagulants as of 2024) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Low-Molecular-Weight Heparin (LMWH) 3.1.2 Direct Thrombin Inhibitor (DTI) 3.1.3 Others 3.2 Global Intravenous Anticoagulants Sales Value by Type 3.2.1 Global Intravenous Anticoagulants Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Intravenous Anticoagulants Sales Value, by Type (2020-2031) 3.2.3 Global Intravenous Anticoagulants Sales Value, by Type (%) (2020-2031) 3.3 Global Intravenous Anticoagulants Sales Volume by Type 3.3.1 Global Intravenous Anticoagulants Sales Volume by Type (2020 VS 2024 VS 2031) 3.3.2 Global Intravenous Anticoagulants Sales Volume, by Type (2020-2031) 3.3.3 Global Intravenous Anticoagulants Sales Volume, by Type (%) (2020-2031) 3.4 Global Intravenous Anticoagulants Average Price by Type (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Clinic 4.1.3 Others 4.2 Global Intravenous Anticoagulants Sales Value by Application 4.2.1 Global Intravenous Anticoagulants Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Intravenous Anticoagulants Sales Value, by Application (2020-2031) 4.2.3 Global Intravenous Anticoagulants Sales Value, by Application (%) (2020-2031) 4.3 Global Intravenous Anticoagulants Sales Volume by Application 4.3.1 Global Intravenous Anticoagulants Sales Volume by Application (2020 VS 2024 VS 2031) 4.3.2 Global Intravenous Anticoagulants Sales Volume, by Application (2020-2031) 4.3.3 Global Intravenous Anticoagulants Sales Volume, by Application (%) (2020-2031) 4.4 Global Intravenous Anticoagulants Average Price by Application (2020-2031) 5 Segmentation by Region 5.1 Global Intravenous Anticoagulants Sales Value by Region 5.1.1 Global Intravenous Anticoagulants Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Intravenous Anticoagulants Sales Value by Region (2020-2025) 5.1.3 Global Intravenous Anticoagulants Sales Value by Region (2026-2031) 5.1.4 Global Intravenous Anticoagulants Sales Value by Region (%), (2020-2031) 5.2 Global Intravenous Anticoagulants Sales Volume by Region 5.2.1 Global Intravenous Anticoagulants Sales Volume by Region: 2020 VS 2024 VS 2031 5.2.2 Global Intravenous Anticoagulants Sales Volume by Region (2020-2025) 5.2.3 Global Intravenous Anticoagulants Sales Volume by Region (2026-2031) 5.2.4 Global Intravenous Anticoagulants Sales Volume by Region (%), (2020-2031) 5.3 Global Intravenous Anticoagulants Average Price by Region (2020-2031) 5.4 North America 5.4.1 North America Intravenous Anticoagulants Sales Value, 2020-2031 5.4.2 North America Intravenous Anticoagulants Sales Value by Country (%), 2024 VS 2031 5.5 Europe 5.5.1 Europe Intravenous Anticoagulants Sales Value, 2020-2031 5.5.2 Europe Intravenous Anticoagulants Sales Value by Country (%), 2024 VS 2031 5.6 Asia Pacific 5.6.1 Asia Pacific Intravenous Anticoagulants Sales Value, 2020-2031 5.6.2 Asia Pacific Intravenous Anticoagulants Sales Value by Region (%), 2024 VS 2031 5.7 South America 5.7.1 South America Intravenous Anticoagulants Sales Value, 2020-2031 5.7.2 South America Intravenous Anticoagulants Sales Value by Country (%), 2024 VS 2031 5.8 Middle East & Africa 5.8.1 Middle East & Africa Intravenous Anticoagulants Sales Value, 2020-2031 5.8.2 Middle East & Africa Intravenous Anticoagulants Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Intravenous Anticoagulants Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Intravenous Anticoagulants Sales Value 6.2.1 Key Countries/Regions Intravenous Anticoagulants Sales Value, 2020-2031 6.2.2 Key Countries/Regions Intravenous Anticoagulants Sales Volume, 2020-2031 6.3 United States 6.3.1 United States Intravenous Anticoagulants Sales Value, 2020-2031 6.3.2 United States Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Intravenous Anticoagulants Sales Value, 2020-2031 6.4.2 Europe Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Intravenous Anticoagulants Sales Value, 2020-2031 6.5.2 China Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.5.3 China Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Intravenous Anticoagulants Sales Value, 2020-2031 6.6.2 Japan Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Intravenous Anticoagulants Sales Value, 2020-2031 6.7.2 South Korea Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Intravenous Anticoagulants Sales Value, 2020-2031 6.8.2 Southeast Asia Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Intravenous Anticoagulants Sales Value, 2020-2031 6.9.2 India Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.9.3 India Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 Aspen Group 7.1.1 Aspen Group Company Information 7.1.2 Aspen Group Introduction and Business Overview 7.1.3 Aspen Group Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.1.4 Aspen Group Intravenous Anticoagulants Product Offerings 7.1.5 Aspen Group Recent Development 7.2 Pfizer 7.2.1 Pfizer Company Information 7.2.2 Pfizer Introduction and Business Overview 7.2.3 Pfizer Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.2.4 Pfizer Intravenous Anticoagulants Product Offerings 7.2.5 Pfizer Recent Development 7.3 Sanofi 7.3.1 Sanofi Company Information 7.3.2 Sanofi Introduction and Business Overview 7.3.3 Sanofi Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.3.4 Sanofi Intravenous Anticoagulants Product Offerings 7.3.5 Sanofi Recent Development 7.4 Mylan 7.4.1 Mylan Company Information 7.4.2 Mylan Introduction and Business Overview 7.4.3 Mylan Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.4.4 Mylan Intravenous Anticoagulants Product Offerings 7.4.5 Mylan Recent Development 7.5 Bayer AG 7.5.1 Bayer AG Company Information 7.5.2 Bayer AG Introduction and Business Overview 7.5.3 Bayer AG Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.5.4 Bayer AG Intravenous Anticoagulants Product Offerings 7.5.5 Bayer AG Recent Development 7.6 Boehringer Ingelheim 7.6.1 Boehringer Ingelheim Company Information 7.6.2 Boehringer Ingelheim Introduction and Business Overview 7.6.3 Boehringer Ingelheim Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.6.4 Boehringer Ingelheim Intravenous Anticoagulants Product Offerings 7.6.5 Boehringer Ingelheim Recent Development 7.7 Daiichi Sankyo 7.7.1 Daiichi Sankyo Company Information 7.7.2 Daiichi Sankyo Introduction and Business Overview 7.7.3 Daiichi Sankyo Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.7.4 Daiichi Sankyo Intravenous Anticoagulants Product Offerings 7.7.5 Daiichi Sankyo Recent Development 7.8 Otsuka 7.8.1 Otsuka Company Information 7.8.2 Otsuka Introduction and Business Overview 7.8.3 Otsuka Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.8.4 Otsuka Intravenous Anticoagulants Product Offerings 7.8.5 Otsuka Recent Development 7.9 Roche 7.9.1 Roche Company Information 7.9.2 Roche Introduction and Business Overview 7.9.3 Roche Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.9.4 Roche Intravenous Anticoagulants Product Offerings 7.9.5 Roche Recent Development 7.10 The Medicines Company 7.10.1 The Medicines Company Company Information 7.10.2 The Medicines Company Introduction and Business Overview 7.10.3 The Medicines Company Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.10.4 The Medicines Company Intravenous Anticoagulants Product Offerings 7.10.5 The Medicines Company Recent Development 7.11 Alexion 7.11.1 Alexion Company Information 7.11.2 Alexion Introduction and Business Overview 7.11.3 Alexion Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.11.4 Alexion Intravenous Anticoagulants Product Offerings 7.11.5 Alexion Recent Development 7.12 Leo Pharma 7.12.1 Leo Pharma Company Information 7.12.2 Leo Pharma Introduction and Business Overview 7.12.3 Leo Pharma Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.12.4 Leo Pharma Intravenous Anticoagulants Product Offerings 7.12.5 Leo Pharma Recent Development 8 Industry Chain Analysis 8.1 Intravenous Anticoagulants Industrial Chain 8.2 Intravenous Anticoagulants Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Intravenous Anticoagulants Sales Model 8.5.2 Sales Channel 8.5.3 Intravenous Anticoagulants Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Intravenous Anticoagulants was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031. Table of Contents1 Market Overview1.1 Intravenous Anticoagulants Product Introduction 1.2 Global Intravenous Anticoagulants Market Size Forecast 1.2.1 Global Intravenous Anticoagulants Sales Value (2020-2031) 1.2.2 Global Intravenous Anticoagulants Sales Volume (2020-2031) 1.2.3 Global Intravenous Anticoagulants Sales Price (2020-2031) 1.3 Intravenous Anticoagulants Market Trends & Drivers 1.3.1 Intravenous Anticoagulants Industry Trends 1.3.2 Intravenous Anticoagulants Market Drivers & Opportunity 1.3.3 Intravenous Anticoagulants Market Challenges 1.3.4 Intravenous Anticoagulants Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Intravenous Anticoagulants Players Revenue Ranking (2024) 2.2 Global Intravenous Anticoagulants Revenue by Company (2020-2025) 2.3 Global Intravenous Anticoagulants Players Sales Volume Ranking (2024) 2.4 Global Intravenous Anticoagulants Sales Volume by Company Players (2020-2025) 2.5 Global Intravenous Anticoagulants Average Price by Company (2020-2025) 2.6 Key Manufacturers Intravenous Anticoagulants Manufacturing Base and Headquarters 2.7 Key Manufacturers Intravenous Anticoagulants Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Intravenous Anticoagulants 2.9 Intravenous Anticoagulants Market Competitive Analysis 2.9.1 Intravenous Anticoagulants Market Concentration Rate (2020-2025) 2.9.2 Global 5 and 10 Largest Manufacturers by Intravenous Anticoagulants Revenue in 2024 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Intravenous Anticoagulants as of 2024) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Low-Molecular-Weight Heparin (LMWH) 3.1.2 Direct Thrombin Inhibitor (DTI) 3.1.3 Others 3.2 Global Intravenous Anticoagulants Sales Value by Type 3.2.1 Global Intravenous Anticoagulants Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Intravenous Anticoagulants Sales Value, by Type (2020-2031) 3.2.3 Global Intravenous Anticoagulants Sales Value, by Type (%) (2020-2031) 3.3 Global Intravenous Anticoagulants Sales Volume by Type 3.3.1 Global Intravenous Anticoagulants Sales Volume by Type (2020 VS 2024 VS 2031) 3.3.2 Global Intravenous Anticoagulants Sales Volume, by Type (2020-2031) 3.3.3 Global Intravenous Anticoagulants Sales Volume, by Type (%) (2020-2031) 3.4 Global Intravenous Anticoagulants Average Price by Type (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Clinic 4.1.3 Others 4.2 Global Intravenous Anticoagulants Sales Value by Application 4.2.1 Global Intravenous Anticoagulants Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Intravenous Anticoagulants Sales Value, by Application (2020-2031) 4.2.3 Global Intravenous Anticoagulants Sales Value, by Application (%) (2020-2031) 4.3 Global Intravenous Anticoagulants Sales Volume by Application 4.3.1 Global Intravenous Anticoagulants Sales Volume by Application (2020 VS 2024 VS 2031) 4.3.2 Global Intravenous Anticoagulants Sales Volume, by Application (2020-2031) 4.3.3 Global Intravenous Anticoagulants Sales Volume, by Application (%) (2020-2031) 4.4 Global Intravenous Anticoagulants Average Price by Application (2020-2031) 5 Segmentation by Region 5.1 Global Intravenous Anticoagulants Sales Value by Region 5.1.1 Global Intravenous Anticoagulants Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Intravenous Anticoagulants Sales Value by Region (2020-2025) 5.1.3 Global Intravenous Anticoagulants Sales Value by Region (2026-2031) 5.1.4 Global Intravenous Anticoagulants Sales Value by Region (%), (2020-2031) 5.2 Global Intravenous Anticoagulants Sales Volume by Region 5.2.1 Global Intravenous Anticoagulants Sales Volume by Region: 2020 VS 2024 VS 2031 5.2.2 Global Intravenous Anticoagulants Sales Volume by Region (2020-2025) 5.2.3 Global Intravenous Anticoagulants Sales Volume by Region (2026-2031) 5.2.4 Global Intravenous Anticoagulants Sales Volume by Region (%), (2020-2031) 5.3 Global Intravenous Anticoagulants Average Price by Region (2020-2031) 5.4 North America 5.4.1 North America Intravenous Anticoagulants Sales Value, 2020-2031 5.4.2 North America Intravenous Anticoagulants Sales Value by Country (%), 2024 VS 2031 5.5 Europe 5.5.1 Europe Intravenous Anticoagulants Sales Value, 2020-2031 5.5.2 Europe Intravenous Anticoagulants Sales Value by Country (%), 2024 VS 2031 5.6 Asia Pacific 5.6.1 Asia Pacific Intravenous Anticoagulants Sales Value, 2020-2031 5.6.2 Asia Pacific Intravenous Anticoagulants Sales Value by Region (%), 2024 VS 2031 5.7 South America 5.7.1 South America Intravenous Anticoagulants Sales Value, 2020-2031 5.7.2 South America Intravenous Anticoagulants Sales Value by Country (%), 2024 VS 2031 5.8 Middle East & Africa 5.8.1 Middle East & Africa Intravenous Anticoagulants Sales Value, 2020-2031 5.8.2 Middle East & Africa Intravenous Anticoagulants Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Intravenous Anticoagulants Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Intravenous Anticoagulants Sales Value 6.2.1 Key Countries/Regions Intravenous Anticoagulants Sales Value, 2020-2031 6.2.2 Key Countries/Regions Intravenous Anticoagulants Sales Volume, 2020-2031 6.3 United States 6.3.1 United States Intravenous Anticoagulants Sales Value, 2020-2031 6.3.2 United States Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Intravenous Anticoagulants Sales Value, 2020-2031 6.4.2 Europe Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Intravenous Anticoagulants Sales Value, 2020-2031 6.5.2 China Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.5.3 China Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Intravenous Anticoagulants Sales Value, 2020-2031 6.6.2 Japan Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Intravenous Anticoagulants Sales Value, 2020-2031 6.7.2 South Korea Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Intravenous Anticoagulants Sales Value, 2020-2031 6.8.2 Southeast Asia Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Intravenous Anticoagulants Sales Value, 2020-2031 6.9.2 India Intravenous Anticoagulants Sales Value by Type (%), 2024 VS 2031 6.9.3 India Intravenous Anticoagulants Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 Aspen Group 7.1.1 Aspen Group Company Information 7.1.2 Aspen Group Introduction and Business Overview 7.1.3 Aspen Group Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.1.4 Aspen Group Intravenous Anticoagulants Product Offerings 7.1.5 Aspen Group Recent Development 7.2 Pfizer 7.2.1 Pfizer Company Information 7.2.2 Pfizer Introduction and Business Overview 7.2.3 Pfizer Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.2.4 Pfizer Intravenous Anticoagulants Product Offerings 7.2.5 Pfizer Recent Development 7.3 Sanofi 7.3.1 Sanofi Company Information 7.3.2 Sanofi Introduction and Business Overview 7.3.3 Sanofi Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.3.4 Sanofi Intravenous Anticoagulants Product Offerings 7.3.5 Sanofi Recent Development 7.4 Mylan 7.4.1 Mylan Company Information 7.4.2 Mylan Introduction and Business Overview 7.4.3 Mylan Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.4.4 Mylan Intravenous Anticoagulants Product Offerings 7.4.5 Mylan Recent Development 7.5 Bayer AG 7.5.1 Bayer AG Company Information 7.5.2 Bayer AG Introduction and Business Overview 7.5.3 Bayer AG Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.5.4 Bayer AG Intravenous Anticoagulants Product Offerings 7.5.5 Bayer AG Recent Development 7.6 Boehringer Ingelheim 7.6.1 Boehringer Ingelheim Company Information 7.6.2 Boehringer Ingelheim Introduction and Business Overview 7.6.3 Boehringer Ingelheim Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.6.4 Boehringer Ingelheim Intravenous Anticoagulants Product Offerings 7.6.5 Boehringer Ingelheim Recent Development 7.7 Daiichi Sankyo 7.7.1 Daiichi Sankyo Company Information 7.7.2 Daiichi Sankyo Introduction and Business Overview 7.7.3 Daiichi Sankyo Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.7.4 Daiichi Sankyo Intravenous Anticoagulants Product Offerings 7.7.5 Daiichi Sankyo Recent Development 7.8 Otsuka 7.8.1 Otsuka Company Information 7.8.2 Otsuka Introduction and Business Overview 7.8.3 Otsuka Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.8.4 Otsuka Intravenous Anticoagulants Product Offerings 7.8.5 Otsuka Recent Development 7.9 Roche 7.9.1 Roche Company Information 7.9.2 Roche Introduction and Business Overview 7.9.3 Roche Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.9.4 Roche Intravenous Anticoagulants Product Offerings 7.9.5 Roche Recent Development 7.10 The Medicines Company 7.10.1 The Medicines Company Company Information 7.10.2 The Medicines Company Introduction and Business Overview 7.10.3 The Medicines Company Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.10.4 The Medicines Company Intravenous Anticoagulants Product Offerings 7.10.5 The Medicines Company Recent Development 7.11 Alexion 7.11.1 Alexion Company Information 7.11.2 Alexion Introduction and Business Overview 7.11.3 Alexion Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.11.4 Alexion Intravenous Anticoagulants Product Offerings 7.11.5 Alexion Recent Development 7.12 Leo Pharma 7.12.1 Leo Pharma Company Information 7.12.2 Leo Pharma Introduction and Business Overview 7.12.3 Leo Pharma Intravenous Anticoagulants Sales, Revenue, Price and Gross Margin (2020-2025) 7.12.4 Leo Pharma Intravenous Anticoagulants Product Offerings 7.12.5 Leo Pharma Recent Development 8 Industry Chain Analysis 8.1 Intravenous Anticoagulants Industrial Chain 8.2 Intravenous Anticoagulants Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Intravenous Anticoagulants Sales Model 8.5.2 Sales Channel 8.5.3 Intravenous Anticoagulants Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(demand)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|